Glaukos provided an investor presentation highlighting commercial progress for iDose TR, the March 2026 Epioxa launch and pipeline expansion across glaucoma, keratoconus and retina.Key Highlights:Original SEC Filing: GLAUKOS Corp [ GKOS ] - 8-K - Aug. 03, 2026This is an AI-powered summary. It may c…
GLAUKOS Corp reported second-quarter 2026 results with revenue of $185.6M, up from $124.1M a year earlier, while the company posted a net loss of $18.4M and diluted net loss per share of $(0.31), modestly improved from the prior-year quarter — 10-Q Summary.Financial HighlightsBusiness HighlightsOri…
Shares of Glaukos GKOS have surged 45.7% since the end of May. The stock has outpaced the industry’s 4% gain and the S&P 500 Index’s 0.9% decline.GKOS stock witnessed a sharp rally after the company announced better-than-expected first-quarter top and bottom-line figures on April 29. However, the s…
